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Objective. Systematic review andmeta-analysis to observe the efficacy and safety of stem cell transplantation therapy in patients with
brain ischemia.Methods. We searched Cochrane Library, PubMed, Ovid, CBM, CNKI, WanFang, and VIP Data from its inception
to December 2015, to collect randomized controlled trials (RCT) of stem cell transplantation for the ischemic stroke. Two authors
independently screened the literature according to the inclusion and exclusion criteria, extracted data, and assessed the risk of
bias. Thereafter, meta-analysis was performed. Results. Sixteen studies and eighteen independent treatments were included in the
current meta-analysis. The results based upon the pooled mean difference from baseline to follow-up points showed that the stem
cell transplantation group was superior to the control group with statistical significance in the neurologic deficits score (NIHSS,
MD = 1.57; 95% CI, 0.64–2.51; 𝐼2 = 57%; 𝑝 = 0.001), motor function (FMA, MD = 4.23; 95% CI, 3.08–5.38; 𝐼2 = 0%; 𝑝 < 0.00001),
daily life ability (Barthel, MD = 8.37; 95% CI, 4.83–11.91; 𝐼2 = 63%; 𝑝 < 0.00001), and functional independence (FIM, MD = 8.89;
95% CI, 4.70–13.08; 𝐼2 = 79%; 𝑝 < 0.0001). Conclusions. It is suggested that the stem cell transplantation therapy for patients
with brain ischemic stroke can significantly improve the neurological deficits and daily life quality, with no serious adverse events.
However, higher quality and larger data studies are required for further investigation to support clinical application of stem cell
transplantation.
1. Introduction
Ischemic stroke, also known as cerebrovascular accident, is
caused by the decreased or interrupted blood supply in the
part of the brain. It is of the dominant diseases affecting
human health and causing themostmortalities, together with
coronary heart disease and cancer [1]. There are more than
fiftymillion people sufferingwith varying degrees of ischemic
stroke in the world; the rate of deaths was close to 10% each
year; meanwhile most survivors were disabled, and not only
did it affect patients physically, but also there are huge impacts
economically and to spirit of patients and their families [1, 2].
Themain pathological manifestation of ischemic stroke is the
ischemic brain tissue (hypoxia/necrosis) for a short time, and
it results in reduced number of neurons, interrupted neural
axon network, and formation of local free oxygen radical
species, leading to harsh environments in the peripheries of
ischemic region, damaging brain self-healing, and eventually
resulting in the permanent loss of nerve tissue or disabling
of brain function. Currently there is no efficient therapy after
stroke, except tPA (tissue plasminogen activator) which is the
only efficient treatment drug in clinical settings [3]. However,
it plays amajor role in the early stage of ischemia, which has a
very short timewindow (4.5 hours, and less than 6 hours) and
can increase the risk of cerebral hemorrhage. In addition, only
approximately 5%of stroke patients can receive this treatment
in the United States [4].
In recent decades, with the rapid development of stem
cell research, many types of stem cells (including adult
stem cells) give rise to more and more attentions in clinic
and showed that transplanted stem cells could promote
therapies for ischemic stroke [5, 6]. Stem cells have high
self-replication and self-differentiation potentials and can
differentiate into many types of cells, such as neural stem
cells (NSC) which may further differentiate into neurons,
astrocytes, and oligodendrocytes, and so forth [7], with lower
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immunogenicity and better histocompatibility. It has been
considered as good tools and the most promising natural
resources for the treatment of brain stroke [8]. Although
many studies regarding stem cells transplantation therapies
have been carried out in experimentalmodels or preclinically,
because of safety, ethical, and therapeutic effect issues, there
is still a long distance for clinical application of stem cells.
Therefore, the purpose of the current study is to systemat-
ically review and evaluate the potential efficacy and safety of
stem cell transplantation therapy for patients with ischemic
brain stroke. We collected the randomized controlled trials
(RCT) of stem cell transplantation for ischemic stroke in
recent 20 years and used systematical review and meta-
analysis approaches to identify the possible publication bias
and to investigate the impact of various aspects of reporting
outcomes in clinical ischemic stroke studies.
2. Methods
2.1. Search Strategy. We searched the literatures in Cochrane
Library, PubMed, Ovid, CBM, CNKI, WanFang, and VIP
Data from its inception to December 2015, to collect ran-
domized controlled trials (RCT) of stem cell transplantation
for ischemic stroke. Published languages contain English and
Chinese.The search words contain stem cell, transplantation,
brain ischemia, and cerebrovascular stroke, and the details
of search strategy are described in the following list (take
PubMed, for instance):
#1 brain ischemia OR cerebrovascular stroke OR
ischemic stroke.
#2 stem cell OR stem cell transplantation.
#3 transplantation.
#4 #1 AND#2AND#3 (filters: randomized controlled
trial; limited: humans).
2.2. Inclusion and Exclusion Criteria. Intervention measure-
ments contain all types of stem cells, such as neural stem
cell (NSC), bone marrowmesenchymal stem cell (MSC), and
umbilical cord mesenchymal stem cell (UC-MSC). Research
subjects (ischemic stroke patients)mustmeetWHOdiagnos-
tic criteria of brain stroke and exclude cerebral hemorrhage
by brain CT or MRI. Each group must have more than
5 patients. The outcomes of treatment from baseline to
follow-up points (or before/after treatment) should contain
National Institutes of Health Stroke Scale (NIHSS), Fugl-
Meyer Assessment (FMA), Barthel index, or Functional
Independence Measure (FIM). We also excluded litera-
ture reviews, meta-analysis, meeting abstracts, case reports,
repeated studies, experimental model researches, and other
diseases researches.
2.3. Data Extraction. Two authors independently screened
the literatures according to the inclusion and exclusion
criteria, extracted data, and assessed the risk of bias. We
extracted these data including authors, year of publication,
patients’ age, gender, time/type of cerebral ischemia, number
of patients (treatment group/control group), type of SCs
(stem cells) intervention, intervention dose, time of admin-
istration, route of delivery, and outcome assessments, mean,
SD (standard deviation) or SE (standard error), and adverse
effects.Wedefined the treatment comparison as the outcomes
in the control group compared to the treated group. If more
than one intervention was given in one study, we regarded
these to be another independent intervention. Furthermore,
if the treatment was administered in multiple doses, we
considered the sum of all doses administered. Finally, if
the functional outcomes were reported for >1 time points,
we only included the last time of assessment. We used the
manual of Cochrane systematic review (5.1.0 RCT bias risk
assessment tools) to evaluate the bias risk of all included
studies.
2.4. Data Analysis/Statistical Analysis. The pooled outcome
difference of stem cell transplantation in the treatment of
ischemic stroke between each treatment group and the con-
trol group used the quantitative data ofmean difference (MD)
or standardized mean difference (SMD) and 95% confidence
interval (CI) tometa-analysis (RevMan 5.3 software). Hetero-
geneity between the results of included studies was analyzed
using 𝜒2 test (significance level 𝛼 = 0.05) and quantitatively
determined the size of heterogeneity by combining with 𝐼2.
If no significant heterogeneity or little heterogeneity between
studieswas found, the fixed effectsmodelwas then used. If the
large statistical heterogeneity between studies was observed,
the random effects model was then used after excluding the
significant clinical heterogeneity. When the heterogeneity
was obvious, the subgroup analysis or sensitivity analysis was
used, or just descriptive analysis. Finally, we used the funnel
plot analysis to evaluate the publication bias.
3. Results
3.1. Study Characteristics. We identified a total of 23 studies
from 855 publications (654 Chinese articles and 201 studies
in English) for this systematic review.The number of patients
is 680 in the stem cell treatment group and 694 in the control
group, respectively. However, there are seven researches
which were excluded due to lack of information or serious
bias, and finally 16 studies (18 independent interventions)
were conducted in the meta-analysis (Figure 1).
There were four interventions with NSC transplantation,
one with UC-MSC, one with PBSC, and twelve combined
with MSC transplantation. There were 6 out of 18 interven-
tions which were performed in acute cerebral ischemia, 7
were done in chronic cerebral ischemic states, and time of
treatment was not mentioned in remaining 5 interventions.
Furthermore, there were 5 of 18 treatments which were
injected in subarachnoid space, 1 through carotid artery, 1 by
intracerebral transplantation, and 11 interventions adminis-
trated intravenously. The duration of follow-up varied from 1
month to 12 months (Table 1).
3.2. Quality Assessment and Bias Risk. Most studies had a
certain risk of bias, especially the Chinese articles in which
the trial design was not rigorous and had more defects in
the blinding and data’s integrity.The English studies have less
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855 articles identified through database searching
(654 Chinese articles and 201 studies in English)
508 of records after duplicates removed
51 of records screened
23 of full-text articles assessed for eligibility
23 of studies included in qualitative synthesis
16 of studies included in quantitative synthesis (meta-analysis)
347 duplicate studies
457 of records excluded
based on title and abstract
28 of full-text articles excluded, with reasons:
(i) Review, meta-analysis, meeting abstract,
pretrial evaluation = 9
(ii) Case report, repetitive study, non-RCT = 16
(iii) Animal model, other disease = 3
7 studies reporting data not suitable for
meta-analysis (e.g., information lack or serious bias)
Figure 1: Flow diagram showing summary of study selection procedure.
Chen et al., 2014 1.6 15 1.6 15 19.8%
Deng et al., 2012 3.2 15 5.5
0.9
3.1 15 10.7%
5.3
6.1
3.8
He, 2012 2.2 20 3.7 2.6 18 15.9%
Liu et al., 2014 6.7 1 29 5.4 2.2 29 22.5%
Prasad et al., 2014 6.2 5.9 60 7.1 6 60 11.4%
2.90 [1.75, 4.05]
0.60 [−1.65, 2.85]
1.60 [0.06, 3.14]
1.30 [0.42, 2.18]
5.3Sun et al., 2008 2.1 20 3.4 2.8 22 16.4%
9.6Xie et al., 2014 9.9 30 4.1 9.3 30 3.3%
189 100.0%Total (95% CI) 189 
−0.90 [−3.03, 1.23]
1.90 [0.41, 3.39]
5.50 [0.64, 10.36]
1.57 [0.64, 2.51]
Study or subgroup ExperimentalMean SD Total
Control
Mean SD Total Weight
Mean difference
IV, random, 95% CI
Mean difference
IV, random, 95% CI
Favours (control) Favours (stem cell)
−10 −5 0 5 10
Test for overall effect: Z = 3.30
Heterogeneity: 𝜏2 = 0.81; 𝜒2 = 14.05, df = 6 (p = 0.03); I2 = 57%
(p = 0.0010)
Figure 2: The effect size of NIHSS improvement across studies by meta-analysis.
bias risk than Chinese articles due to the trial design which
followed the RCT policy (Table 2).
3.3. Meta-Analysis and Effect Evaluation. We performed the
pooled data for meta-analysis and found that 7 interventions
reported NIHSS improvement [10, 13, 14, 18–21], 6 interven-
tions determined FMA functional optimization [12, 15, 17,
18, 24], 9 treatments pointed out Barthel index enhancement
[9, 12, 15, 17–19, 21, 24], and 6 treatment groups showed FIM
functional improvement [11, 16, 22–24]. The results of meta-
analysis were as follows: NIHSS (MD = 1.57, 95% CI 0.64–
2.51, 𝐼2 = 57%, 𝑝 = 0.001, Figure 2), FMA (MD = 4.23,
95% CI 3.08–5.38, 𝐼2 = 0%, 𝑝 < 0.00001, Figure 3), Barthel
(MD = 8.37, 95% CI 4.83–11.91, 𝐼2 = 63%, 𝑝 < 0.00001,
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Table 2: Study quality or risk of bias report.
Author Year Randomallocation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcome
assessment
Complete
outcome data
Nonselective
reporting
No other bias
risk
Bang et al. [9] 2005 √ √ √ √ √ √ √
Sun et al. [10] 2008 √ Χ Χ Χ Χ Χ Χ
Niu et al. [11] 2010 √ Χ Χ Χ Χ Χ Χ
Bhasin et al. [12] 2011 Χ Χ Χ √ √ √ √
Deng et al. [13] 2012 Χ Χ Χ Χ Χ Χ Χ
He [14] 2012 √ Χ Χ Χ Χ Χ Χ
Bhasin et al. [15] 2012 Χ Χ Χ √ √ √ √
Xiao [16] 2013 √ Χ Χ Χ Χ Χ Χ
Bhasin et al. [17] 2013 Χ Χ Χ √ √ √ √
Liu et al. [18] 2014 √ Χ Χ Χ Χ Χ Χ
Xie et al. [19] 2014 √ Χ Χ Χ Χ Χ Χ
Chen et al. [20] 2014 √ √ √ √ √ √ √
Prasad et al. [21] 2014 √ √ √ √ √ √ Χ
Zhang et al. [22] 2015 √ Χ Χ Χ Χ Χ Χ
Shen [23] 2015 √ Χ Χ Χ Χ Χ Χ
Cai et al. [24] 2015 √ √ Χ Χ Χ Χ Χ
Total (95% CI)
Bhasin et al., 2011 20 6.6 6 17.3 6.9 6 2.3% 2.70 [−4.94, 10.34]
Bhasin et al., 2012 20.4 5 12 17.2 5.6 12 7.3% 3.20 [−1.05, 7.45]
Bhasin et al., 2013-1 20.2 8.7 14 16.7 8.1 20 4.0% 3.50 [−2.28, 9.28]
Bhasin et al., 2013-2 18 7.4 6 16.7 8.1 20 2.8% 1.30 [−5.60, 8.20]
31Cai et al., 2015 9.6 21 22.7 9.6 21 3.9% 8.30 [2.49, 14.11]
24.2Liu et al., 2014 2.4 29 19.9 2.6 29 79.7% 4.30 [3.01, 5.59]
108 100.0% 4.23 [3.08, 5.38]88 
Study or subgroup ExperimentalMean SD Total
Control
Mean SD Total Weight
Mean difference
IV, fixed, 95% CI
Mean difference
IV, fixed, 95% CI
Favours (control) Favours (stem cell)
−20 −10 0 10 20
Test for overall effect: Z = 7.20
Heterogeneity: 𝜒2 = 3.03, df = 5 (p = 0.70); I2 = 0%
(p < 0.00001)
Figure 3: The effect size of improved FMA across studies by meta-analysis.
Figure 4), and FIM (MD = 8.89, 95% CI 4.70–13.08, 𝐼2 =
79%, 𝑝 < 0.0001, Figure 5). All the outcomes after the
merger were in favor of stem cell transplantation group, and
each of the differences was statistically significant. Only four
studies reported adverse effects, which includedmild fever or
headache and these were self-relieved within a short period.
Then we performed subgroup analysis for further evalua-
tion of the clinical efficacy based on several clinical variables,
and we focused on four clinical variables: time/type of
cerebral ischemia, type of SCs interventions, route of delivery,
and follow-up period. Each clinical variable was analyzed by
interactingwithNIHSS or Barthel indexwhichwere reported
consistently, including evaluation of subgroup effects and
heterogeneity analysis (Tables 3 and 4), and the results were in
favor of the nonvein injected group (e.g., subarachnoid space
and carotid artery administration) and long-time follow-up
period (more than 6 months). However, when the time and
type of cerebral ischemia were analyzed, NIHSS and Barthel
index were improved in chronic cerebral ischemia and acute
cerebral ischemic stroke patients, respectively. Due to the
reason that most studies usedMSC transplantation, the effect
of SCs type interventions could not be obtained.
4. Discussion
Stem cells have several special biological characteristics, such
as proliferation ability, multidirectional differentiation, and
good histocompatibility, and numerous studies have focused
on the therapeutic potential of stem cell therapy for various
refractory diseases. With the rise of stem cell therapy in
recent years, different types of stem cells have been widely
investigated and applied for ischemic stroke therapy, espe-
cially with a sharp increase in NSC andMSC transplantation.
Lees et al. evaluated 117 studies on preclinical experimental
model of stem cell therapy by meta-analysis and showed
that stem cell transplantation had improved the animals’
neural function and reduced the area of cerebral infarct [25].
Vu et al. studied the efficacy of preclinical mesenchymal
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Total (95% CI)
Bang et al., 2005 55.4 18 5 25.5 19.4 25 3.5% 29.90 [12.39, 47.41]
Bhasin et al., 2011 29.8 11 6 24.2 10 6 6.4%
Bhasin et al., 2012 30.7 9.7 12 20.5 10 12 10.8% 
Bhasin et al., 2013-1 29.7 11 14 21.5 20 11.9% 
26.4Bhasin et al., 2013-2 9.5 6 21.5
9.7
9.7 20 9.7% 
Cai et al., 2015 7.6 21 26.8 6.5
2.5
21 17.4%
36.7
33.5
Liu et al., 2014 1.9 29 31.5 29 22.7%
38.1Prasad et al., 2014 27
30
60 36.1 26 60 8.7%
Xie et al., 2014 33.6 18 12.3 18.9 30 8.9% 21.30 [11.96, 30.64]
100.0% 183 223 8.37 [4.83, 11.91]
5.60 [−6.30, 17.50]
10.20 [2.32, 18.08]
8.20 [1.04, 15.36]
4.90 [−3.81, 13.61]
6.70 [2.42, 10.98]
5.20 [4.06, 6.34]
2.00 [−7.48, 11.48]
Study or subgroup ExperimentalMean SD Total
Control
Mean SD Total Weight
Mean difference
IV, random, 95% CI
Mean difference
IV, random, 95% CI
Favours (control) Favours (stem cell)
−20 −10 0 10 20
Test for overall effect: Z = 4.63
Heterogeneity: 𝜏2 = 14.02; 𝜒2 = 21.33, df = 8 (p = 0.006); I2 = 63%
(p < 0.00001)
Figure 4: The effect size of Barthel index improvement across studies by meta-analysis.
Total (95% CI)
21.9 10 21 11.6 9.9 21 15.5%
5 7.5 16 1 7.3 20 17.4%
11 14.6 16 5.2 15.3 16 9.5%
Cai et al., 2015
Niu et al., 2010
Shen, 2015
11.9 7.5 78 6.5 8.7 82 21.0%
21.2 6.5 14 11.4 6.2 28 18.6%
28.5 8.2 18 11.4 6.2 28
Xiao, 2013 
Zhang et al., 2015 iv
Zhang et al., 2015 sa 18.1% 17.10 [12.67, 21.53]
10.30 [4.28, 16.32]
4.00 [−0.87, 8.87]
5.80 [−4.56, 16.16]
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9.80 [5.69, 13.91]
195163 100.0% 8.89 [4.70, 13.08]
Study or subgroup ExperimentalMean SD Total
Control
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−20 −10 0 10 20
Test for overall effect: Z = 4.16
Heterogeneity: 𝜏2 = 20.14; 𝜒2 = 24.37, df = 5 (p = 0.0002); I2 = 79%
(p < 0.0001)
Figure 5: The effect size of improved FIM across studies by meta-analysis.
Table 3: The correlations of NIHSS and clinical variables across
studies by subgroup and heterogeneity analysis.
Subgroup Mean difference (95% CI) 𝐼2 (%)
Patients’ characteristics
Acute stoke 0.93 (−0.65, 2.51) 57
Chronic stroke 2.28 (1.47, 3.09) 6
Cell type
MSC 1.25 (0.35, 2.14) 38
Non-MSC 2.9 (1.75, 4.05) —
Route of delivery
Intravenous injection 1.0 (−0.18, 2.17) 41
Non-IV 2.38 (0.77, 3.99) 71
Follow-up period
<6 months 1.41 (0.76, 2.06) 0
≥6 months 2.07 (−1.10, 5.24) 82
stromal cells transplantation therapy for ischemic stroke
models and demonstrated the favorable (MSC) outcomes,
and the outcomes were related with the type of MSC source,
route of delivery, time of injection, and intervention dose
[26]. Because of safety, efficacy, and ethical reasons, there
still remains a long way before the stem cell therapy can
be actually used in clinical settings. Liu et al. searched the
MSC transplantation therapy for cerebral ischemic patients
Table 4: The correlations of Barthel and clinical variables across
studies by subgroup and heterogeneity analysis.
Subgroup Mean difference (95% CI) 𝐼2 (%)
Patients’ characteristics
Acute stoke 12.61 (2.39, 22.84) 84
Chronic stroke 7.19 (4.18, 10.20) 0
Cell type
MSC 8.37 (4.83, 11.91) 63
Non-MSC — —
Route of delivery
Intravenous injection 7.58 (3.85, 11.30) 30
Non-IV 12.56 (−3.16, 28.27) 91
Follow-up period
<6 months 5.2 (4.06, 6.34) —
≥6 months 9.52 (4.92, 14.13) 58
and found 6 studies (332 patients); they confirmed that MSC
transplantation could significantly improve patients’ neural
functional defects, motor functions, and daily life abilities
[27]. Jeong et al. analyzed the safety and efficacy of stem
cell transplantation therapy for brain stroke; they included
14 researches which independently use stem cell therapy (not
RCT studies) and determined that stem cell therapy improved
the patients’ grades of NIHSS, Barthel index, and Rankin
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functions [28]. All those studies confirmed the therapeutic
potential of stem cells clinically.
Here we have searched the RCT studies of stem cell
transplantation for ischemic stroke and used meta-analysis
approach to identify the possible publication bias and to
investigate the clinical efficacy of reported outcomes (NIHSS,
FMA, Barthel and FIM) in ischemic stroke studies. A total of
23 studies recruited 1374 patients, and the patients of ischemic
stroke must have met WHO diagnostic criteria of brain
stroke. Cerebral hemorrhage was ruled out in these patients
by brain CT or MRI. Each group must have more than 5
patients.The type of interventions containedNSC,MSC,UC-
MSC, and PBSC. Finally, 16 articles and 18 treatment inter-
ventions have been analyzed by meta-analysis; the outcomes
of treatment from baseline to follow-up points included
NIHSS, FMA, Barthel index, or FIM which all improved to
varying degrees, with fewer adverse effects. Then we used
4 clinical variables (time/type of cerebral ischemia, type of
SCs interventions, route of delivery, and follow-up period)
to interact with 2 outcome indicators (NIHSS and Barthel)
and found that patients who received SCs transplantation
via subarachnoid space, carotid artery, and intracerebral
were superior to those in which SCs were administered
intravenously, and long-term follow-up was associated with
better outcome than short-term follow-up. But there was no
relation with time and type of cerebral infarct or type of SC
interventions with functional improvement. Due to the fact
that most studies had defects in blinding, data’s integrity, and
trial designs, ourmeta-analysis might have some risks of bias.
In conclusion, the current meta-analysis of clinical stud-
ies of SCs therapy for ischemic stroke demonstrated sig-
nificant and favorable effects on behavioral, motor, and life
quality outcomes. However, because of few clinical trials
for stem cell transplantation therapy, lower frequency of
patient participation, and possible bias issues in trial designs,
there is possibility of bias occurrence.Therefore, further high
quality and bigger data studies are needed in the future to
investigate the possibilities of stem cells transplantation in
clinical settings.
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